metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
ovarian cancer (OC) ovarian cancer (OC)
mOC - L1 - all population metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - all population
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	-18 [-425; 389] /10000 109/651 vs. 110/650	-285 [-828; 259] /10000 323/651 vs. 341/650	-
mOC - L1 - PDL1 positive metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - PDL1 positive
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	-43 [-541; 454] /10000 57/391 vs. 59/393	-793 [-1489; -96] /10000 167/391 vs. 199/393	-
metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	-420 [-2369; 1528] /10000 21/49 vs. 24/51	-1257 [-2605; 92] /10000 39/49 vs. 47/51	-
versus pegylated liposomal doxorubicin
	avelumab alone vs. pegylated liposomal doxorubicin	1	324 [-675; 1324] /10000 109/188 vs. 104/190	1613 [742; 2483] /10000 154/188 vs. 125/190	-
	avelumab plus pegylated liposomal doxorubicin vs. pegylated liposomal doxorubicin	1	-48 [-1052; 956] /10000 102/188 vs. 104/190	549 [-386; 1483] /10000 134/188 vs. 125/190	-
metastatic/advanced OC (mOC) - maintenance (M) metastatic/advanced OC (mOC) - maintenance (M)